aiqbench analysis
Isomorphic Labs leverages advanced AI to automate complex protein-ligand binding pocket discovery, a critical bottleneck in drug development where it claims superior accuracy over existing tools like AlphaFold. This funding round validates the commercial viability of using deep learning models to map dynamic cellular surfaces and predict molecular interactions for new therapies. The company's progress highlights how specialized AI platforms are transforming computational chemistry and accelerating the pace of pharmaceutical research.
Alphabet spinoff Isomorphic Labs reportedly raising funding at up to $50B valuation
Isomorphic Labs Ltd., an Alphabet Inc. spinoff working to accelerate drug discovery, is said to be raising a new funding round. The Bloomberg report that revealed the discussions today didn’t specify the size of the deal. The paper’s sources did, however, divulge that Isomorphic is eyeing a valuation of between $40 billion and $50 billion. […] The post Alphabet spinoff Isomorphic Labs reportedly raising funding at up to $50B valuation appeared first on SiliconANGLE.
Isomorphic Labs Ltd., an Alphabet Inc. spinoff working to accelerate drug discovery, is said to be raising a new funding round. The Bloomberg report that revealed the discussions today didn’t specify the size of the deal. The paper’s sources did, however, divulge that Isomorphic is eyeing a valuation of between $40 billion and $50 billion. Isomorphic’s flagship product…
Excerpt shown under the publisher's RSS terms · 58 words · full text and figures are on the publisher's site
Related coverage
The Facebook whistleblower behind ‘The Social Reckoning’ says Zuckerberg is ‘playing with fire’ on AI
Fortune · Oct 8, 2026
OpenAI revenue falls short, models play hopscotch and Trump cracks down on tech green cards
SiliconANGLE · Oct 9, 2026
News
Quantum Computing Report · Jun 7, 2026
People might start believing in radical life extension soon
LessWrong · Jul 20, 2026